Acute Coronary Syndrome

Clinical Trial Finder

Many patients with acute coronary syndrome are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Ticagrelor;   Drug: Prasugrel
Sponsors:   Korea University Anam Hospital;   AstraZeneca
Not yet recruiting - verified June 2015

The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome

Conditions:   Acute Coronary Syndrome;   Bleeding;   Novel Anti-platelets;   Ticagrelor;   Clopidogrel
Intervention:   Drug: Ticagrelor
Sponsors:   Aintree University Hospitals NHS Foundation Trust;   Liverpool Heart and Chest Hospital NHS Foundation Trust;   Royal Liverpool and Broadgreen University Hospitals NHS Trust;   Countess of Chester NHS Foundation Trust;   St Helens & Knowsley Teaching Hospitals NHS Trust
Recruiting - verified June 2015

CER-001 Atherosclerosis Regression ACS Trial

Condition:   Acute Coronary Syndromes
Intervention:   Drug: CER-001
Sponsors:   Cerenis Therapeutics, SA;   South Australian Health and Medical Research Institute
Not yet recruiting - verified June 2015

OCT-Features in Culprit and Not Culprit Coronary Plaque in ACS Patients

Conditions:   Acute Coronary Syndrome;   Culprit Plaque;   Non Culprit Plaque
Intervention:   Other: optical coherence tomography
Sponsor:   Azienda Ospedaliera Città della Salute e della Scienza di Torino
Recruiting - verified June 2015

Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions

Conditions:   Acute Myocardial Infarction;   Acute Coronary Syndrome
Intervention:   Other: APN-led Telemedicine
Sponsors:   National University Heart Centre, Singapore;   National University Hospital, Singapore
Not yet recruiting - verified June 2015

Impact of Care Transition on Medication Adherence in Cardiac Patients

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   King's College London
Not yet recruiting - verified June 2015

Active Clearance Technology (ACT) II German Multicenter Trial

Condition:   Heart Surgery
Intervention:   Device: Blood drainage post cardiac surgery using PleuraFlow System
Sponsors:   Prof. Dr. Theodor Fischlein;   ClearFlow, Inc.
Not yet recruiting - verified June 2015

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

Condition:   Cost Sharing, Acute Coronary Syndrome,
Intervention:   Other: Study voucher card
Sponsors:   AstraZeneca;   Duke Clinical Research Institute
Recruiting - verified June 2015

Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes

Conditions:   Chronic Obstructive Pulmonary Disease;   Acute Coronary Syndromes
Intervention:   Other: screening test
Sponsor:   University Hospital of Ferrara
Active, not recruiting - verified July 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

Conditions:   Acute Leukemia;   Myelodysplasia
Interventions:   Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Not yet recruiting - verified June 2015

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Study of a Quality Improvement Toolkit in Kerala, India, Among Hospitals Treating Acute Coronary Syndrome Patients

Condition:   Acute Coronary Syndrome
Intervention:   Behavioral: Quality Improvement Toolkit
Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified July 2015

Phase I/II Trial of Early Infusion of Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections

Conditions:   Chronic Lymphocytic Leukemia;   CML (Chronic Myelogenous Leukemia);   MDS (Myelodysplastic Syndrome);   Acute Lymphoblastic Leukemia;   AML (Acute Myelogenous Leukemia)
Intervention:   Biological: MVST
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?

Condition:   Acute Coronary Syndome
Interventions:   Other: Blood Test;   Other: EndoPAT - endothelial assessment
Sponsor:   Jennifer Rossington
Recruiting - verified June 2015

Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Graft Versus Host Disease;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Anemia With Excess Blasts
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified July 2015

MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis II;   Mucopolysaccharidosis VI;   Mucopolysaccharidosis VII;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Glycoprotein Metabolic Disorders;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy;   Peroxisomal Disorders;   Osteopetrosis;   Sphingolipidosis;   Gangliosidosis;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann Pick B;   Niemann Pick C Subtype 2;   I-cell Disease
Interventions:   Procedure: blood stem cell transplant;   Drug: Rabbit Anti-Thymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine A (CSA);   Drug: Methylprednisolone;   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte-Colony Stimulating Factor (G-CSF);   Drug: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Drug: N-acetylcysteine;   Drug: Celecoxib;   Drug: Vitamin E;   Drug: Alpha Lipoic Acid
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting - verified June 2015

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

Condition:   Non-ST Elevation Acute Coronary Syndrome
Interventions:   Drug: ticagrelor;   Drug: clopidogrel
Sponsor:   AstraZeneca
Terminated - verified June 2015

Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI

Condition:   Non ST Segment Elevation Acute Coronary Syndrome
Intervention:   Drug: ticagrelor
Sponsor:   General Hospital of Chinese Armed Police Forces
Recruiting - verified January 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified June 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified June 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified June 2015

Modafinil and Cognitive Function in POTS

Condition:   Postural Tachycardia Syndrome
Interventions:   Drug: Placebo;   Drug: Modafinil;   Drug: Propranolol
Sponsor:   Vanderbilt University
Recruiting - verified June 2015

Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion

Condition:   Acute Coronary Syndrome
Interventions:   Drug: ticagrelor;   Drug: Eptifibatide
Sponsors:   University of Alabama at Birmingham;   AstraZeneca
Active, not recruiting - verified June 2015

ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial

Condition:   End Stage Renal Failure on Dialysis
Interventions:   Drug: Spironolactone;   Drug: Placebo
Sponsors:   University Hospital, Brest;   Central Hospital, Nancy, France;   Institut National de la Santé Et de la Recherche Médicale, France
Recruiting - verified June 2015

Efficacy and Safety Study of Ticagrelor

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsor:   General Hospital of Chinese Armed Police Forces
Recruiting - verified March 2015

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome;   Pancytopenia;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Secondary Acute Myeloid Leukemia
Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified June 2015

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Conditions:   Adult Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Chronic Myelomonocytic Leukemia-1;   Chronic Myelomonocytic Leukemia-2;   Previously Treated Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide;   Drug: Vorinostat
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting - verified March 2015

Immune Globulin Subcutaenous (Human), 20%

Condition:   Primary Immunodeficiency Diseases (PID)
Interventions:   Biological: Immune Globulin Subcutaneous (Human), 20%;   Biological: Immune Globulin Intravenous (Human), 10%;   Biological: Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)
Sponsor:   Baxalta US Inc.
Completed - verified April 2015

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients

Condition:   Septic Shock
Interventions:   Drug: Dobutamine;   Drug: Placebo
Sponsor:   Pontificia Universidad Catolica de Chile
Completed - verified June 2015

Phase 2/3 Study of IGSC, 20% in PIDD

Condition:   Primary Immunodeficiency Diseases(PIDD)
Interventions:   Biological: Immune Globulin Intravenous (Human), 10% Solution;   Drug: Immune Globulin Subcutaneous (Human), 20% Solution
Sponsor:   Baxalta US Inc.
Completed - verified April 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified July 2015

BAY81-8781, I.V. Aspirin in the Indication of Acute Coronary Syndrome (ACS)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV;   Drug: D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV;   Drug: Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet
Sponsor:   Bayer
Completed - verified June 2015

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

Conditions:   Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions:   Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified April 2015

A Clinical Trial of IntensiVE Dialysis

Conditions:   Renal Replacement Therapy;   Renal Dialysis;   End Stage Kidney Disease;   End Stage Renal Disease;   Uremia
Intervention:   Procedure: haemodialysis
Sponsors:   The George Institute;   National Health and Medical Research Council, Australia;   Baxter Healthcare Corporation
Completed - verified June 2013

Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome

Conditions:   Myelodysplastic Syndrome (MDS);   Severe Aplastic Anemia (SAA)
Interventions:   Other: Umbilical Cord Blood;   Other: Haploidentical Stem Cells;   Device: Miltenvi CliniMACs CD34 Reagent System
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2015

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Hematologic Neoplasms;   Neural Tube Defects;   Myeloproliferative Disorders
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified September 2014

The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction

Conditions:   Coronary Disease;   Ventricular Dysfunction, Left
Interventions:   Drug: Ivabradine;   Drug: Placebo
Sponsor:   Institut de Recherches Internationales Servier
Completed - verified June 2015

Get CardioSmart

You're Invited